Moreover, the panel has the six biomarkers recently proposed by the Food and Drug Administration and the European Medicines Evaluation Agency for use as indicators of nephrotoxic AKI through the Critical Path Initiave (albumin, β2-microglobulin, clusterin, cystatin C, KIM-1 and trefoil factor-3-TFF-3-) [16]. The gene discussed is CLU; the disease is acute kidney injury.